| Private Placement / Financing Transactions
Kriya: The company raised $313.3 million of venture funding from undisclosed investors on August 15, 2025. The company is an operator of a gene therapeutics business intended to design and develop gene therapies with a pipeline that spans across ophthalmology, oncology, rare disease, and chronic disease.
SetPoint Medical: The company raised $115 million of Series D venture funding in a deal led by Elevage Medical Technologies and Ally Bridge Group on August 12, 2025, putting the company’s pre-money valuation at $365 million. Northwell Health, Abbott, Norwest, Sprig Equity, and other undisclosed investors also participated in the round. The company is a developer of implantable neuromodulation devices designed to treat chronic inflammatory diseases.
Corner Therapeutics: The company raised $58.5 million of Series A venture funding in a deal led by Ziff Capital Partners on August 11, 2025. Sandia Holdings, Tanis Venture Management, and Cockrell Interests also participated in the round. The company is a biotechnology business focused on developing novel immunotherapies to treat cancer and infectious diseases.
Gameto: The company raised $44 million of Series C venture funding in a deal led by Overwater Ventures on August 12, 2025, putting the company’s pre-money valuation at $199 million. Future Ventures (San Francisco), BOLD Capital Partners, Insight Partners (New York), Two Sigma Ventures, RA Capital Management, Ingeborg Investments, Pontiva Healthcare Partners, Portfolia, Pags Group, Arcadia Investment Partners, and other undisclosed investors also participated in the round. The company is an operator of a biotechnology business intended to develop novel therapies for infertility, menopause, and other reproductive health issues.
Mabylon: The company raised CHF 30 million of Series B venture funding through a combination of equity and debt from undisclosed investors on August 12, 2025. The company is an operator of a biotechnology business intended to harness the therapeutic potential of naturally occurring human antibodies to treat allergies, inflammation, and neurodegenerative diseases.
Jocasta Neurosciences: The company raised $35 million of Series A venture funding in a deal led by True Ventures on August 12, 2025, putting the company’s pre-money valuation at $17 million. VC Investment Partners, Moore Strategic Ventures, SC8 Investments, Glentura, Yagan Family Foundation and other undisclosed investors also participated in the round. The company is an operator of a biotech business intended to develop treatments for cognitive decline associated with various forms of dementia.
Tahoe: The company raised an estimated $35 million of Series A venture funding in a deal led by Amplify Partners on August 11, 2025, putting the company’s pre-money valuation at an estimated $96 million. Databricks Ventures, Conviction Partners, Wing Venture Capital, General Catalyst, AIX Ventures, Overlap Holdings, Civilization Ventures, and Mubadala Investment Company also participated in the round. The company is a biotechnology business focused on improving drug discovery by building AI models of human cells and using them to find better treatments for patients.
Citizen Health: The company raised $30 million of Series A venture funding in a deal led by 8VC on August 14, 2025. Transformation Capital, Wavemaker Three-Sixty Health, Headline, and Chan Zuckerberg Initiative also participated in the round. The company is a developer of an online healthcare data platform designed to help patients collect, organize and share their medical records digitally.
Arintra: The company raised $21 million of Series A venture funding in a deal led by Peak XV Partners on August 12, 2025. Endeavor Health, Counterpart Ventures, TEN13, Spider Capital, Y Combinator and other undisclosed investors also participated in the round. The company is a developer of a medical coding platform designed to simplify patient intake and auto-generate documentation for remote clinics.
Goodpath: The company raised $16.2 million of Series A venture funding from undisclosed investors on August 11, 2025, putting the company’s pre-money valuation at $23 million. The company is a developer of a personalized self-care program designed to improve the lives of people managing chronic conditions.
Synthpop: The company raised $15 million of Series A venture funding from undisclosed investors on August 11, 2025, putting the company’s pre-money valuation at $45 million. The company is an operator of an artificial intelligence-based healthcare workflow platform designed to provide real-time feedback and summarization.
Angiex: The company raised $10.9 million of venture funding from William Paseman and undisclosed investors on August 14, 2025. The company is a developer of vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis.
PrognomIQ: The company raised $10 million of venture funding from undisclosed investors on August 11, 2025. The company is a developer of medical test products designed for the detection and treatment of cancer and other complex diseases.
Peerbridge Health: The company raised $7.2 million of venture funding from undisclosed investors on August 14, 2025. The company is a manufacturer of a wearable multi-channel electrocardiogram patch designed for continuous vital sign monitoring.
Securisyn Medical: The company raised $5.6 million of venture funding from undisclosed investors on August 11, 2025. The company is a developer of an airway stabilization system designed to provide improved breathing for ventilated patients.
Kestrel Therapeutics: The company raised $5 million of venture funding from undisclosed investors on August 11, 2025. The company is a developer of oncological drugs designed to treat RAS-driven cancers and provide new therapies for mutated oncogenic cancer targets.
Bryn Pharma: The company raised $4.7 million of venture funding from undisclosed investors on August 14, 2025. The company is an operator of a biotechnology business intended to offer nasal-based epinephrine for anaphylaxis.
LayerBio: The company raised an undisclosed amount of venture funding from PainReform on August 13, 2025. The company is a developer of novel therapies designed to address unmet needs in the field of ophthalmology.
|
